A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Inclusion Criteria:

• Participants must be at least 18 years of age at the time of signing the informed consent.
• At least 1 measurable diseases based on CT scan or MRI
• Renal function values
• Participants who have an ECOG PS score of 0, 1 or 2.
• Be willing to provide a fresh tissue taken at current relapse at screening period.
• Meet laboratory values at Screening i.e., ANC, Platelets, Corrected serum calcium, AST and ALT, Total bilirubin etc
• Contraceptive use by [men and women] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Women of childbearing potential and fertile men must agree to use highly effective contraceptive methods • At least 1 measurable diseases based on CT scan or MRI
• Capable of giving signed informed consent
• Health Information Access: Capable of providing access to personal health information via HIPAA authorization (US only).
• Legal Status: Not under any administrative or legal supervision or institutionalization due to regulatory or juridical order.

Exclusion Criteria:

• Medical Conditions
• History of prior allogenic transplant.
• Presence of Grade 2 peripheral neuropathy with pain.
• Impaired cardiac function or clinically significant cardiac disease at Screening
• Known active CNS involvement or clinical signs of meningeal involvement.
• Evidence of HIV infection.
• Active chronic HBV/HCV infection,
• Participants with positive anti-HBc must have a negative HBV-DNA quantification test result to be enrolled.
• Receipt of any anti-tumor therapy within three weeks or at least five half-lives prior to the Screening visit, whichever is shorter.
• Toxicities from prior anticancer therapies that have not resolved to Grade 1 or less except for abnormal clinical values alopecia and peripheral neuropathy (participants with Grade 1 or 2 neuropathy without pain are eligible for enrollment).
• Use of systemic corticosteroids exceeding 10 mg/day of prednisone or equivalent within 14 days prior to the first dose